William Blair & Company
DNA icon

William Blair & Company’s Ginkgo Bioworks DNA Stock Holding History

William Blair & Company’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-825
Closed -$11K – 1839
2024
Q2 		$11K Buy
825
+72
+10% +$2.15K ﹤0.01% 1738
2024
Q1 		$35K Buy
753
+43
+6% +$2.23K ﹤0.01% 1638
2023
Q4 		$48K Sell
710
-83
-10% -$5.08K ﹤0.01% 1586
2023
Q3 		$57.4K Sell
793
-48
-6% -$3.84K ﹤0.01% 1570
2023
Q2 		$62.5K Sell
841
-26
-3% -$1.54K ﹤0.01% 1570
2023
Q1 		$46.1K Hold
867
– – ﹤0.01% 1593
2022
Q4 		$58.6K Sell
867
-162
-16% -$14.9K ﹤0.01% 1558
2022
Q3 		$128K Buy
1,029
+216
+27% +$25.7K ﹤0.01% 1468
2022
Q2 		$77K Sell
813
-149
-15% -$18.2K ﹤0.01% 1577
2022
Q1 		$155K Buy
962
+452
+89% +$88K ﹤0.01% 1573
2021
Q4 		$170K Buy
+510
New +$242K ﹤0.01% 1611

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

William Blair & Company's DNA Position: Q3 2024 in Review

William Blair & Company sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 825 shares — an estimated $11K sold.

William Blair & Company first reported a position in DNA in Q4 2021 and held it in 11 quarters. The position peaked at $170K in Q4 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • William Blair & Company reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • William Blair & Company sold 825 Ginkgo Bioworks shares in Q3 2024, an estimated $11K.
  • William Blair & Company first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 11 quarters.
  • William Blair & Company's Ginkgo Bioworks position peaked at $170K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on William Blair & Company's 13F filing for Q3 2024, filed 12 Nov 2024.